Following a full submission
AWMSG advice |
|||
| Status: Superseded | |||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED NOVEMBER 2017. Refer to TA497: Golimumab for treating non-radiographic axial spondyloarthritis for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
|||
|
|||
Medicine details |
|||
| Medicine name | golimumab (Simponi®) | ||
| Formulation | 50 mg, 100 mg solution for injection | ||
| Reference number | 1562 | ||
| Indication | Treatment of adults with severe, active non radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs) |
||
| Company | Merck Sharp & Dohme Ltd | ||
| BNF chapter | Musculoskeletal & joint diseases | ||
| Assessment type | Full | ||
| Status | Superseded | ||
| Advice number | 2316 | ||
| NMG meeting date | 20/07/2016 | ||
| AWMSG meeting date | 21/09/2016 | ||
| Ratification by Welsh Government | 04/10/2016 | ||
| Date of issue | 05/10/2016 | ||
| NICE guidance | TA497: Golimumab for treating non-radiographic axial spondyloarthritis (external website - opens in new window) |
||